2020年新疆地区猪繁殖与呼吸综合征病毒抗体检测与分析

为了解2020年新疆地区猪繁殖与呼吸障碍综合征病毒（PRRSV）抗体水平及其消长规律,本试验采用间接酶联免疫吸附试验（ELISA）法对1 218份血清中PRRSV免疫抗体水平进行检测和分析。结果显示,PRRSV抗体平均阳性率为78.49%（956/1218）,高于国家规定标准（70%）。S/P的平均值为1.22±0.84,变异系数为69.45%。不同类别猪群抗体平均阳性率在59.19%~91.50%之间,有一定的差异。在调查的10个规模化养殖场中,9个场PRRSV免疫抗体阳性率达到国家标准。不同类别猪群PRRSV变异系数较高,需进一步对现有的免疫程序进行调整和完善,确保各猪群健康。     

2020年新疆地区规模化猪场猪PCV2抗体检测与分析

为了解新疆地区2020年规模化猪场猪圆环病毒2型的免疫抗体水平,选择新疆地区6个规模化猪场,针对不同日龄段的猪采集血清样品333份,采用猪圆环病毒2型ELISA抗体检测方法进行抗体检测分析。结果发现,2020年新疆地区规模化猪场猪圆环病毒2型平均抗体阳性率为77.78%（259/333）,平均抗体阳性率符合国家标准。但各猪场免疫效果参差不齐,抗体阳性率最高的为A场,阳性率达100.00%;阳性率最低的为C场,仅48.78%,低于（70%）的国家标准。不同日龄段的猪抗体水平也存在一定的差异,抗体阳性率最高为种公猪,达96.30%;而保育阶段猪抗体水平最低,仅有47.92%,低于国家标准。     

2019—2020年新疆部分地区猪PCV2的抗体水平检测及分析

为了解2019—2020年新疆地区猪圆环病毒病2型（PCV2）抗体水平及其消长规律,本试验采用间接酶联免疫吸附试验（ELISA）方法对475份血清中PCV2免疫抗体水平进行检测和分析。结果显示,PCV2抗体平均阳性率为69.68%（331/475）,未达到国家规定标准（70%）。S/P的平均值为1.56。不同类别猪群抗体平均阳性率在42.50%~86.67%之间,有一定的差异。在调查的5个规模化养殖场中,仅有2个场PCV2免疫抗体阳性率达到国家标准。各场应根据抗体检测结果,进一步对现有的免疫程序进行调整和完整,确保各猪群健康。     

Study on the Change Rule of Egg Yolk Antibody in Laying Hens after First Immunization by Japanese Encephalitis Virus

The purpose of this experiment was to study the immunization rule of the egg yolk antibody affected by different vaccines,immunization dose and injection ways and further to discuss the optimal immunization procedures of the laying hens for the preparation of egg yolk antibody against swine Japanese encephalitis virus.180 brown laying hens without any vaccines were selected and divided into 18 groups randomly,each group of 10 hens.Groups 1,2 were the control groups,injected with the sterile saline;Groups 3 to 10 were injected with subcutaneous or intramuscular injection,and the vaccine was injected with 0.2,0.5,1.0 and 1.5 mL successively.Groups 11 to 18 were also adopted two kinds of injection,followed by the same dose of vaccine immunization.Six eggs of each experimental group were gathered before immune day and after 3,7,10,14,18,21 and 28 days,the egg yolk antibody was extracted and the titer was determined.As a result,the egg yolk antibody titers of groups 1 to 6,11 and 12 were all 0,and no significant immune response produced;The hens from 7 to 10 groups were injected with the inactivated vaccine.After 7 days,the average antibody titer reached the peak,and the duration of the antibody was 14 days.The hens from 13 to 18 groups were injected with the attenuated virus vaccine.After 14 days,the average antibody titer reached the highest value,and the duration of the antibody was 21 days.The egg yolk antibody titers were not significantly different in the two compared experiment groups with the same injection dose but with different injection ways (P>0.05).With the same injection way of each experiment group,and the difference was significant (P>0.05).Compared with some groups with the same injection and vaccine,the titer of yolk antibody was gradually increased with the increase of the immune dose,and the difference was significant (P<0.05).The results showed that,no matter intramuscular or subcutaneous injection,in order to produce a significant immune response to hens,the immune antigen dose was 1.0 mL inactivated vaccine or 0.5 mL attenuated vaccine at least.Compared with the attenuated and inactivated vaccine,inactivated vaccine stimulated the body to produce the antibody faster,but the maintenance time was shorter;The lower dose of attenuated vaccine could stimulate the body to produce antibodies,but the speed was slower,the maintenance time was longer.     

Preparation and Identification of Canine Parvovirus NY Strain VP2 Protein Polyclonal Antibody

This study was aimed to prepare canine parvovirus (CPV) VP2 protein polyclonal antibody.The recombinant expression vector pET28a-CPV-VP2 was constructed and transfromed into E.coli BL21 (DE3),the expression of recombinant proteins was induced by IPTG from which the fusion protein was identified by SDS-PAGE.The target protein was purified and emulsify with adjuvant,the prepared immunogen was inoculated into rabbit by subcutaneous injections to prepare of VP2 protein specific polyclonal antibody.The immuno-activity,titers,neutralization titers of the prepared polyclonal antibody were determined by immunoperoxidase monolayer assay (IPMA).The results showed that the expressed recombinant protein VP2 (rVP2) existed in the form of inclusion body with a molecular weight of 72 ku.The prepared polyclonal antibody titer was 1 600 dilution,the virus titer was 10⁷ TCID₅₀/mL,the neutralizing titer was 1∶2 884.The antibodies showed specific reaction with CPV.In conclusion,rVP2 specific polyclonal antibody showed wonderful immunocompetence,specificity and neutralizing activity,providing foundation for the development of genetic vaccine and clinical therapeutic method.     

倍他米松ELISA检测方法的建立

为建立倍他米松(BET)ELISA检测方法,先使BET与琥珀酸酐反应,再采用活化酯法与牛血清白蛋白(BSA)偶联制备免疫原;其次,利用免疫动物获得多克隆抗体,经Sephrose 4B-proteinA方法对抗体进行纯化;最后,建立倍他米松ELISA检测方法。结果表明,免疫抗原偶联成功,获得了亲和力较高的多克隆抗血清,间接竞争ELISA测定其滴度为102 400、IC15为6.60×10-5 ng/mL和IC50为0.97ng/mL。该方法适用于残留在动物性食品中的BET现场大批量检测。     

Effects of dietary L-threonine levels on antioxidant capacity,digestive enzyme activities,and antibody production of Xinyang green-shell laying hens

Xinyang green-shell laying hens (n = 720), 32 wk of age were allocated to 5 dietary treatments groups, each of which included 6 replicates of 24 hens. The control group was given a basal corn-peanut-soybean meal diet containing 0.47% L-threonine (L-Thr). L-Thr levels of the experimental groups were 0.57, 0.67, 0.77, and 0.87%, respectively. The trial lasted 10 wk. Serum concentrations of total superoxide dismutases (T-SOD) and superoxide dismutases (SOD) were maximized at 0.67% L-Thr group. The 0.57% L-Thr group had the highest serum total antioxidative capacity (T-AOC), while the 0.67% L-Thr group had the lowest serum malondialdehyde (MDA) concentration. Hens fed 0.67% L-Thr of the diet resulted in the highest SOD and T-AOC levels in the liver. The activity of amylase and lipase in the jejunum was maximized at 0.77% L-Thr level. Hens fed 0.77% L-Thr in the diet resulted in the highest IgM and IgG levels in the jejunum. In conclusion, we suggest that a L-Thr level above 0.67% may have had an antioxidant capacity and positive effect on digestive enzyme activities and antibody production in the jejunum of Xinyang green-shell laying hens.     

A prospective,randomized, double-blind,placebo-controlled multisite,parallel-group field study in dogs with osteoarthritis conducted in the United States of America evaluating bedinvetmab,a canine anti-nerve growth factor monoclonal antibody

ObjectiveBedinvetmab, a fully canine anti-nerve growth factor monoclonal antibody, was evaluated in dogs for control of osteoarthritis-related pain in a study conducted to support registration in the USA.Study designRandomized, double-blind, placebo-controlled, multicenter, parallel-group study.AnimalsGeneral practice client-owned dogs with osteoarthritis (n = 272).MethodsDogs were block randomized 1:1 to placebo (saline, n = 137) or bedinvetmab (n = 135; 0.5–1.0 mg kg^–1) administered subcutaneously, once monthly. The primary end point, day 28 Canine Brief Pain Inventory (CBPI) treatment success (TS), required pain severity score (PSS; 0–10) decrease ≥1 and pain interference score (PIS; 0–10) decrease ≥ 2. CBPI TS rates [and number needed to treat (NNT)], change in scores [and standardized effect size (ES)], change in quality of life (QoL) and bedinvetmab half-life were calculated.ResultsSignificant (p < 0.05) improvement with bedinvetmab over placebo occurred (days 28, 42, 56, 84) for CBPI TS. Of cases evaluable for day 28 CBPI TS (placebo, n = 131; bedinvetmab, n = 128), success rates were 36.6% and 47.4%, respectively (p = 0.0410) (NNT, 9.3; PSS and PIS ES, 0.3). CBPI TS increased after the second dose in both groups, plateaued for bedinvetmab at day 42 and decreased for placebo beginning day 84. Day 84 NNT (4.3), PSS (0.4) and PIS (0.5) showed continued improvement with monthly dosing. After the first dose, mean (± standard deviation) bedinvetmab half-life was 19.1 (8.3) days. Adverse events were similar between groups and not considered treatment-related. There was a significant effect of bedinvetmab versus placebo on all CBPI components (PIS, PSS, QoL).Conclusions and clinical relevanceThese results corroborated those previously reported and provide further support of safety and effectiveness of bedinvetmab (0.5–1.0 mg kg^–1) administered subcutaneously at monthly intervals to dogs for control of osteoarthritis-related pain.     

新形势下对我国金融机构反洗钱的思考

金融机构肩负着货币收支、汇兑业务工作的同时也担负了反洗钱的艰巨任务,金融机构如何完成这一任务也就成为当前的一项重要课题。本文认为我国金融机构仍需继续加强金融业反洗钱的法制建设;强化行业监管,提高监管实效;建立健全反洗钱组织体系以及建立反洗钱的激励机制。